GKOS (Glaukos) Total Current Assets: $485.8 Mil (As of Mar. 2026)


GKOS Glaukos Corp GKOS
80 GF Score
Price $144.42
GF Value $135.47
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Total Current Assets?

Glaukos GKOS +1.30% 80 Total Current Assets is $485.8 Mil as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $135.47 (Fairly Valued). The stock has 6 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Glaukos's total current assets for the quarter that ended in Mar. 2026 was $485.8 Mil.

Glaukos  (NYSE:GKOS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Glaukos's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=276.685-222.398+0.75 * 119.691+0.5 * 62.384
=175.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Total Current Assets Related Terms

Glaukos Total Current Assets Historical Data

* Premium members only.

The historical data trend for Glaukos's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Total Current Assets Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 486.13 443.86 395.46 449.79 474.98

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 444.54 436.07 454.77 474.98 485.75
GKOS
80GF Score
Glaukos Corp GKOS
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Glaukos's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=278.76+108.608+63.564+24.052
=475.0

Glaukos's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=276.685+119.691+62.384+26.993
=485.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $485.8 Mil mean?
Glaukos (GKOS) has a Total Current Assets of $485.8 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Glaukos and its competitors.
Is Glaukos' Total Current Assets too high?
Glaukos' current Total Current Assets is $485.8 Mil. Overall, Glaukos has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Total Current Assets compare to LIVN and BIO?
Glaukos' Total Current Assets of $485.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Devices & Instruments company?
A good Total Current Assets depends on the Medical Devices & Instruments industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Glaukos and its competitors. Glaukos's current Total Current Assets is $485.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.47, compared to a current price of $144.42 — trading 6.6% above its estimated fair value. The current Total Current Assets is $485.8 Mil. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Glaukos (GKOS), the current Total Current Assets is $485.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $144.42 is trading 6.6% above its estimated GF Value™ of $135.47. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Total Current Assets: $485.8 Mil
  • GF Value™: $135.47 vs. price of $144.42 (6.6% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score

Get the complete analysis for GKOS

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$144.42
Price
$135.47
GF Value